Abstract
Novel clinical strategies need to be evolved, as pathogens, especially the ones that infect the human, develop resistance. To do so, host pathogen biology needs to be clearly understood and this can be done using a nematode worm, Caenorhabditis elegans, which harbours the same virulent microbes. Over several decades, the worm has been used to study host-microbe interaction with reference to immune response of the worm, antimicrobial molecules secreted, cell death in the worm body, quorum sensing network of the bacteria and fast or slow worm death. This mini review gives a bird’s eye view of the directions that have been taken in these areas to date. Currently, the worm has been proposed to be an ideal model for high throughput screening of natural and synthetic drugs against a variety of bacteria. Experimental systems that allow this screening have been patented. Caenorhabditis elegans, thus, is one of the very effective models for studying pathogens that infect human.
Keywords: Anti-bacterial molecules, Caenorhabditis elegans, drug screening, human gut pathogens, innate immunity model organism.
Recent Patents on Biotechnology
Title:Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Volume: 10 Issue: 2
Author(s): Nabila Sorathia and Medha S. Rajadhyaksha
Affiliation:
Keywords: Anti-bacterial molecules, Caenorhabditis elegans, drug screening, human gut pathogens, innate immunity model organism.
Abstract: Novel clinical strategies need to be evolved, as pathogens, especially the ones that infect the human, develop resistance. To do so, host pathogen biology needs to be clearly understood and this can be done using a nematode worm, Caenorhabditis elegans, which harbours the same virulent microbes. Over several decades, the worm has been used to study host-microbe interaction with reference to immune response of the worm, antimicrobial molecules secreted, cell death in the worm body, quorum sensing network of the bacteria and fast or slow worm death. This mini review gives a bird’s eye view of the directions that have been taken in these areas to date. Currently, the worm has been proposed to be an ideal model for high throughput screening of natural and synthetic drugs against a variety of bacteria. Experimental systems that allow this screening have been patented. Caenorhabditis elegans, thus, is one of the very effective models for studying pathogens that infect human.
Export Options
About this article
Cite this article as:
Sorathia Nabila and Rajadhyaksha S. Medha, Caenorhabditis elegans: A Model for Studying Human Pathogen Biology, Recent Patents on Biotechnology 2016; 10 (2) . https://dx.doi.org/10.2174/1872208310666160727151853
DOI https://dx.doi.org/10.2174/1872208310666160727151853 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Quorum Sensing in Staphylococcus spp.
Current Pharmaceutical Design Combating Vancomycin Resistance in Bacteria: Targeting the D-ala-D-ala Dipeptidase VanX
Infectious Disorders - Drug Targets Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells
Protein & Peptide Letters Current Status of Imaging Infections with Radiolabeled Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Models of In-Vivo Bacterial Infections for the Development of Antimicrobial Peptide-based Drugs
Current Topics in Medicinal Chemistry Antibiotic Use in Children - Off-Label Use
Current Drug Targets Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Biosynthesis and Genetic Engineering of Lipopeptide Antibiotics Related to Daptomycin
Current Topics in Medicinal Chemistry Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Current Research on Opioid Receptor Function
Current Drug Targets Structural Insights into Chitinolytic Enzymes and Inhibition Mechanisms of Selective Inhibitors
Current Pharmaceutical Design Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets First Report on the Characteristics of Methicillin-Resistant <i>Staphylococcus Capitis</i> Isolates and an NRCS-A-clone Related Isolate Obtained from Iranian Children
Infectious Disorders - Drug Targets Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design Ruptured Multiple Mycotic Aneurysms Following Infective Endocarditis: Effectiveness of Catheter-based Techniques Using N-butyl Cyanoacrylate in a Hemorrhage-induced Coagulopathy
Current Medical Imaging